CDK4, cyclin dependent kinase 4, 1019

N. diseases: 433; N. variants: 8
Disease: Liposarcoma, Pleomorphic ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Biomarker disease BEFREE Negative MDM2/CDK4 staining in our case argues against the possibility of dedifferentiated liposarcoma and further supports the diagnosis of true PL. 27778364 2017
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 GeneticVariation disease BEFREE In extramammary sites, these subtypes have different biological behaviours and distinct genetic alterations: MDM2 and CDK4 amplification in well-differentiated liposarcoma, and polyploidy with complex structural rearrangements in pleomorphic liposarcoma. 26542423 2016
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Biomarker disease BEFREE Coexpression of MDM2 and CDK4 distinguishes DDLPS from PLPS. 24227706 2014
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Therapeutic disease CTD_human Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. 23569312 2013
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Biomarker disease CTD_human Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. 23569312 2013
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Therapeutic disease CTD_human Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. 20601955 2010
CUI: C0205825
Disease: Liposarcoma, Pleomorphic
Liposarcoma, Pleomorphic 		0.330 Biomarker disease CTD_human Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. 20601955 2010